Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2017, Article ID 4245613, 13 pages
https://doi.org/10.1155/2017/4245613
Research Article

Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach

1Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
2Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan

Correspondence should be addressed to Jian Wang; moc.liame@gnawnaij and Maosheng Cheng; ten.362@gnehcsm

Received 23 August 2017; Accepted 26 September 2017; Published 26 December 2017

Academic Editor: Tingjun Hou

Copyright © 2017 Xiangyu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Tian, Y. Li, D. Li et al., “Modeling compound-target interaction network of traditional chinese medicines for type II diabetes mellitus: Insight for polypharmacology and drug design,” Journal of Chemical Information and Modeling, vol. 53, no. 7, pp. 1787–1803, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Tahtah, S. G. Wubshet, K. T. Kongstad et al., “High-resolution PTP1B inhibition profiling combined with high-performance liquid chromatography-high-resolution mass spectrometry-solid-phase extraction-nuclear magnetic resonance spectroscopy: proof-of-concept and antidiabetic constituents in crude extract of Eremophila lucida,” Fitoterapia, vol. 110, pp. 52–58, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Onoda, W. Li, K. Higai, and K. Koike, “Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents,” BMC Complementary and Alternative Medicine, vol. 14, article 64, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Yamazaki, K. Ukai, and M. Namikoshi, “Asperdichrome, an unusual dimer of tetrahydroxanthone through an ether bond, with protein tyrosine phosphatase 1B inhibitory activity, from the Okinawan freshwater Aspergillus sp. TPU1343,” Tetrahedron Letters, vol. 57, no. 7, pp. 732–735, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Salmeen, J. N. Andersen, M. P. Myers et al., “Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate,” Nature, vol. 423, no. 6941, pp. 769–773, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Denu and J. E. Dixon, “Protein tyrosine phosphatases: mechanisms of catalysis and regulation,” Current Opinion in Chemical Biology, vol. 2, no. 5, pp. 633–641, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. Bartholomew, C. W. Jones, A. Benware, J. Chernoff, and S. E. LaFlamme, “Regulation of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310,” Experimental Cell Research, vol. 311, no. 2, pp. 294–306, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Böhmer, S. Szedlacsek, L. Tabernero, A. Östman, and J. Den Hertog, “Protein tyrosine phosphatase structure-function relationships in regulation and pathogenesis,” FEBS Journal, vol. 280, no. 2, pp. 413–431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Barford, A. K. Das, and M.-P. Egloff, “The structure and mechanism of protein phosphatases: insights into catalysis and regulation,” Annual Review of Biophysics, vol. 27, pp. 133–164, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Alonso, J. Sasin, N. Bottini et al., “Protein tyrosine phosphatases in the human genome,” Cell, vol. 117, no. 6, pp. 699–711, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. K. Baskaran, N. Goswami, S. Selvaraj, V. S. Muthusamy, and B. S. Lakshmi, “Molecular dynamics approach to probe the allosteric inhibition of PTP1B by chlorogenic and cichoric acid,” Journal of Chemical Information and Modeling, vol. 52, no. 8, pp. 2004–2012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. D. Klaman, O. Boss, O. D. Peroni et al., “Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice,” Molecular and Cellular Biology, vol. 20, no. 15, pp. 5479–5489, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Krishnan, K. Krishnan, C. R. Connors et al., “PTP1B inhibition suggests a therapeutic strategy for Rett syndrome,” The Journal of Clinical Investigation, vol. 125, no. 8, pp. 3163–3177, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Wiesmann, K. J. Barr, J. Kung et al., “Allosteric inhibition of protein tyrosine phosphatase 1B,” Nature Structural & Molecular Biology, vol. 11, no. 8, pp. 730–737, 2004. View at Publisher · View at Google Scholar
  15. S. Liu, L.-F. Zeng, L. Wu et al., “Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors,” Journal of the American Chemical Society, vol. 130, no. 50, pp. 17075–17084, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Ala, L. Gonneville, M. C. Hillman et al., “Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics,” The Journal of Biological Chemistry, vol. 281, no. 43, pp. 32784–32795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Han, M. Belley, C. I. Bayly et al., “Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 11, pp. 3200–3205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. P. Wilson, Z.-K. Wan, W.-X. Xu et al., “Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site,” Journal of Medicinal Chemistry, vol. 50, no. 19, pp. 4681–4698, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Choy, Y. Li, L. E. S. F. Machado et al., “Conformational rigidity and protein dynamics at distinct timescales regulate PTP1B activity and allostery,” Molecular Cell, vol. 65, no. 4, pp. 644–658.e5, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. R.-J. Li, Y.-L. Wang, Q.-H. Wang, J. Wang, and M.-S. Cheng, “In silico design of human IMPDH inhibitors using pharmacophore mapping and molecular docking approaches,” Computational and Mathematical Methods in Medicine, vol. 2015, Article ID 418767, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Ala, L. Gonneville, M. Hillman et al., “Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B,” The Journal of Biological Chemistry, vol. 281, no. 49, pp. 38013–38021, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Z.-K. Wan, J. Lee, R. Hotchandani et al., “Structure-based optimization of protein tyrosine phosphatase-1B inhibitors: capturing interactions with arginine 24,” ChemMedChem, vol. 3, no. 10, pp. 1525–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Charlier, J.-P. Hénichart, F. Durant, and J. Wouters, “Structural insights into human 5-lipoxygenase inhibition: Combined ligand-based and target-based approach,” Journal of Medicinal Chemistry, vol. 49, no. 1, pp. 186–195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. R. A. Friesner, R. B. Murphy, M. P. Repasky et al., “Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6177–6196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. R.-J. Li, J. Wang, Z. Xu et al., “Computational insight into p21-activated kinase 4 inhibition: a combined ligand—and structure-based approach,” ChemMedChem, vol. 9, no. 5, pp. 1012–1022, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. F. Moretto, S. J. Kirincich, W. X. Xu et al., “Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors,” Bioorganic & Medicinal Chemistry, vol. 14, no. 7, pp. 2162–2177, 2006. View at Publisher · View at Google Scholar
  27. Z. Dolatkhah, S. Javanshir, A. S. Sadr, J. Hosseini, and S. Sardari, “Synthesis, molecular docking, molecular dynamics studies, and biological evaluation of 4H-chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives as potential antileukemic agents,” Journal of Chemical Information and Modeling, vol. 57, no. 6, pp. 1246–1257, 2017. View at Publisher · View at Google Scholar
  28. S. Tian, X. Wang, L. Li et al., “Discovery of novel and selective adenosine A2A receptor antagonists for treating parkinson's disease through comparative structure-based virtual screening,” Journal of Chemical Information and Modeling, vol. 57, no. 6, pp. 1474–1487, 2017. View at Publisher · View at Google Scholar
  29. S. Tian, H. Sun, Y. Li, P. Pan, D. Li, and T. Hou, “Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures,” Journal of Chemical Information and Modeling, vol. 53, no. 10, pp. 2743–2756, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Tian, H. Sun, P. Pan et al., “Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility,” Journal of Chemical Information and Modeling, vol. 54, no. 10, pp. 2664–2679, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Barford, A. J. Flint, and N. K. Tonks, “Crystal structure of human protein tyrosine phosphatase 1B,” Science, vol. 263, no. 5152, pp. 1397–1404, 1994. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Kumar, R. N. Shinde, D. Ajay, and M. E. Sobhia, “Probing interaction requirements in PTP1B inhibitors: a comparative molecular dynamics study,” Journal of Chemical Information and Modeling, vol. 50, no. 6, pp. 1147–1158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Salmeen, J. N. Andersen, M. P. Myers, N. K. Tonks, and D. Barford, “Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B,” Molecular Cell, vol. 6, no. 6, pp. 1401–1412, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. Jia, D. Barford, A. J. Flint, and N. K. Tonks, “Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B,” Science, vol. 268, no. 5218, pp. 1754–1758, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Li, L. Wang, and D. Shi, “The design strategy of selective PTP1B inhibitors over TCPTP,” Bioorganic & Medicinal Chemistry, vol. 24, no. 16, pp. 3343–3352, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. J. N. Andersen, O. H. Mortensen, G. H. Peters et al., “Structural and evolutionary relationships among protein tyrosine phosphatase domains,” Molecular and Cellular Biology, vol. 21, no. 21, pp. 7117–7136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. T. R. Burke Jr. and K. Lee, “Phosphotyrosyl mimetics in the development of signal transduction inhibitors,” Accounts of Chemical Research, vol. 36, no. 6, pp. 426–433, 2003. View at Publisher · View at Google Scholar · View at Scopus